DOCSLIB.ORG

Ependymoma Associated with a Good Prognosis in Immune Gene And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ependymoma Associated with a Good Prognosis in Immune Gene And Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma This information is current as Andrew M. Donson, Diane K. Birks, Valerie N. Barton, Qi of September 27, 2021. Wei, Bette K. Kleinschmidt-DeMasters, Michael H. Handler, Allen E. Waziri, Michael Wang and Nicholas K. Foreman J Immunol 2009; 183:7428-7440; Prepublished online 16 November 2009; doi: 10.4049/jimmunol.0902811 Downloaded from http://www.jimmunol.org/content/183/11/7428 References This article cites 51 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/183/11/7428.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma1 Andrew M. Donson,2*§ Diane K. Birks,‡§ Valerie N. Barton,*§ Qi Wei,*§ Bette K. Kleinschmidt-DeMasters,† Michael H. Handler,‡§ Allen E. Waziri,‡ Michael Wang,*§ and Nicholas K. Foreman*‡§ Approximately 50% of children with ependymoma will suffer from tumor recurrences that will ultimately lead to death. Devel- opment of more effective therapies and patient stratification in ependymoma mandates better prognostication. In this study, tumor gene expression microarray profiles from pediatric ependymoma clinical samples were subject to ontological analyses to identify outcome-associated biological factors. Histology was subsequently used to evaluate the results of ontological analyses. Ontology analyses revealed that genes associated with nonrecurrent ependymoma were predominantly immune function-related. Addition- ally, increased expression of immune-related genes was correlated with longer time to progression in recurrent ependymoma. Of Downloaded from those genes associated with both the nonrecurrent phenotype and that positively correlated with time to progression, 95% were associated with immune function. Histological analysis of a subset of these immune function genes revealed that their expression was restricted to a subpopulation of tumor-infiltrating cells. Analysis of tumor-infiltrating immune cells showed increased infil- tration of CD4؉ T cells in the nonrecurrent ependymomas. No genomic sequences for SV40, BK, JC, or Merkel polyomaviruses were found in nonrecurrent ependymoma. This study reveals that up-regulation of immune function genes is the predominant http://www.jimmunol.org/ ontology associated with a good prognosis in ependymoma and it provides preliminary evidence of a beneficial host proinflam- matory and/or Ag-specific immune response. The Journal of Immunology, 2009, 183: 7428–7440. pendymoma (EPN),3 the third most common brain tumor recur from overly aggressive treatments. Identification of prognos- of children, is treated by surgical resection and radiation tic markers for EPN may have the added benefit of providing in- E therapy (1, 2). Complete resection, often requiring “sec- sight into the biological mechanisms of tumorigenesis, which ond-look” surgery, is critical for a favorable outcome (3, 4). Ra- could be exploited for the development of more effective therapies. diation therapy is also standard, and omission of this results in a To date, study of candidate prognostic markers for pediatric higher number of tumor recurrences (4, 5). Chemotherapy has so EPN have largely been confined to histological grading according by guest on September 27, 2021 far shown little or no benefit. Unfortunately, Ͼ50% of children to World Health Organization (WHO) tumor classification criteria treated with the standard regimen will suffer from tumor recur- (7–11), as well as to molecular markers such as Ki-67 (12, 13), rence, which will ultimately result in death (6). This high failure survivin (14, 15), human telomerase reverse transcriptase (16), and rate represents one of the most significant problems in pediatric nucleolin (4). More recently, global molecular analyses such as neuro-oncology. Despite unfavorable outcome in more than half of array comparative genomic hybridization (17, 18) and gene ex- pediatric EPN patients, little progress has been made in the past 20 pression profiling (17, 19–21) have been employed to discover years either in treatment or identification of robust prognostic fac- prognostic chromosomal aberrations or gene expression signa- tors. The ability to identify up-front those EPN patients whose tures. These global studies have produced an even wider range of tumor will recur would allow clinicians to try more aggressive candidate prognostic markers, although none to date have identi- treatment regimens, better stratify patients on various treatment fied a biological mechanism of recurrence. Despite these numerous protocols, and spare those children whose tumors are unlikely to studies, there remains no predictor of tumor recurrence in EPN that is robustly reproducible from study to study. The driving hypoth- esis for this study is that gene expression patterns differ between *Department of Pediatrics, †Departments of Pathology and Neurology, and ‡Depart- ment of Neurosurgery, University of Colorado Denver, Aurora, CO 80045; and §The good and bad prognosis EPN, the details of which will allow for Children’s Hospital, Denver, CO 80045 better prognostication and provide insights into the biology of re- Received for publication August 25, 2009. Accepted for publication October 5, 2009. currence. To achieve this, tumor gene expression profiling com- The costs of publication of this article were defrayed in part by the payment of page bined with gene ontology analysis was used as an unbiased ap- charges. This article must therefore be hereby marked advertisement in accordance proach to identify sets of functionally related genes that were with 18 U.S.C. Section 1734 solely to indicate this fact. associated with clinical outcome in EPN clinical samples. Using 1 This work was supported by the Tanner Seebaum Foundation. this approach, it was found that an up-regulation of immune func- 2 Address correspondence and reprint requests to Andrew M. Donson, Department of tion-related genes was the predominant ontology associated with a Pediatrics, University of Colorado Denver, Mail Stop 8302, P.O. Box 6511, Aurora, CO 80045. E-mail address: [email protected] complete response to therapy. 3 Abbreviations used in this paper: EPN, ependymoma; AIF-1, allograft inhibitory factor-1; DAVID; Database for Annotation, Visualization, and Integrated Discovery; FDR, false discovery rate; FFPE, formalin-fixed paraffin-embedded; gcRMA, Gene- Materials and Methods Chip robust multiarray average; GO, Gene Ontology; GSEA, Gene Set Enrichment Patient cohort Analysis; IHC, immunohistochemistry; TIL, tumor-infiltrating lymphocyte; TTP, time to progression; GOTERM, Gene Ontology Project term. Surgical tumor samples were obtained from 19 patients who presented between 1997 and 2007 for treatment at The Children’s Hospital (Denver, Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00 CO) who were diagnosed with EPN according to WHO guidelines (22). All www.jimmunol.org/cgi/doi/10.4049/jimmunol.0902811 The Journal of Immunology 7429 identified by the user as significantly associated with a particular phenotype Table I. Patient cohort demographic and tumor detailsa or variable. Immunohistochemistry (IHC) Patient TTP Grade Age at ID Outcome (months) (WHO) Location Gender Dx (years) IHC was performed on 5-␮m FFPE tumor tissue sections. Slides were deparaffinized and then subjected to optimal Ag retrieval protocols. Sub- 80 Non — II IF M 2 110 Rec 31 II IF M 2 sequent steps were performed using the EnVision-HRP kit (Dako) on a 135 Rec 6 III ST F 14 Dako autostainer according to standard protocol. Incubation with primary 195 Rec 24 III IF M 2 Ab was performed for 2 h. The following dilutions of primary Ab were 242 Rec 1 III ST F 4 used, and applied to the sections for 1 h: 1/250 allograft inhibitory factor-1 246 Rec 35 II IF M 2 (AIF-1) (01-1974) from Waco Pure Chemicals; 1/50 HLA-DR (LN3) and 285 Non — III ST F 5.5 1/40 CD4 (IF6) from Novocastra; 1/100 CD8 (C8/144B), 1/200 CD20 306 Non — II IF M 13 ϩ 318 Non — III IF F 2 (L26), 1/50 CD45 (2B11 PD7/26), and 1/100 CD68 (PG-M1) from 319 Rec 51 II IF F 6 Dako. Each of these Abs stained a discrete subpopulation of cells that were 364 Rec 35 II IF M 13 distributed throughout the parenchyma of the tumor. Slides were analyzed 388 Non — III ST M 11 with the Olympus BX40 microscope, ϫ40 objective lens. Images were 392 Non — II IF F 1 captured using an Optronics MicroFire 1600 ϫ 1200 camera and Picture- 393 Rec 18 II IF F 6 Frame 2.3 imaging software (Optronics). Infiltrating cell abundancies were 416 Non — III ST M 5 measured as the mean number of positive staining cells per five fields of 419 Non — II IF M 3 459 Non — III IF F 0.5 view and differential expression between groups was determined using a 483 Rec 23 II IF M 7 Student’s t test with a p value cutoff of 0.05. 507 Rec 5 III IF M 5 Quantitative PCR for viral sequences Downloaded from a — denotes that tumor did not recur. Non, nonrecurrent; Rec, recurrent; WHO, World Health Organization tumor grade classification; IF, infratentorial; ST, supra- Quantitative PCR was performed for SV40, BK, JC, and Merkel polyoma- tentorial; Dx, diagnosis.
Load more

Recommended publications
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Human Lectins, Their Carbohydrate Affinities and Where to Find Them
    biomolecules Review Human Lectins, Their Carbohydrate Affinities and Where to Review HumanFind Them Lectins, Their Carbohydrate Affinities and Where to FindCláudia ThemD. Raposo 1,*, André B. Canelas 2 and M. Teresa Barros 1 1, 2 1 Cláudia D. Raposo * , Andr1 é LAQVB. Canelas‐Requimte,and Department M. Teresa of Chemistry, Barros NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829‐516 Caparica, Portugal; [email protected] 12 GlanbiaLAQV-Requimte,‐AgriChemWhey, Department Lisheen of Chemistry, Mine, Killoran, NOVA Moyne, School E41 of ScienceR622 Co. and Tipperary, Technology, Ireland; canelas‐ [email protected] NOVA de Lisboa, 2829-516 Caparica, Portugal; [email protected] 2* Correspondence:Glanbia-AgriChemWhey, [email protected]; Lisheen Mine, Tel.: Killoran, +351‐212948550 Moyne, E41 R622 Tipperary, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +351-212948550 Abstract: Lectins are a class of proteins responsible for several biological roles such as cell‐cell in‐ Abstract:teractions,Lectins signaling are pathways, a class of and proteins several responsible innate immune for several responses biological against roles pathogens. such as Since cell-cell lec‐ interactions,tins are able signalingto bind to pathways, carbohydrates, and several they can innate be a immuneviable target responses for targeted against drug pathogens. delivery Since sys‐ lectinstems. In are fact, able several to bind lectins to carbohydrates, were approved they by canFood be and a viable Drug targetAdministration for targeted for drugthat purpose. delivery systems.Information In fact, about several specific lectins carbohydrate were approved recognition by Food by andlectin Drug receptors Administration was gathered for that herein, purpose. plus Informationthe specific organs about specific where those carbohydrate lectins can recognition be found by within lectin the receptors human was body.
    [Show full text]
  • Ependymomas in Young Children
    Provide d by Ependymomas in Young Children Lead Contributors: Su Gülsün Berrak, MD Rejin Kebudi, MD Istanbul University, Oncology Institute Istanbul, Turkey Ibrahim Qaddoumi, MD, MS St. Jude Children’s Research Hospital Memphis, Tennessee, United States of America A. Epidemiology Ependymomas are the third most common type of brain tumor that affects children. 1 In a recent study of Turkish children, ependymomas accounted for approximately 13.6% of all brain tumors.2 More than 50% of all patients with ependymomas are younger than 5 years of age, and 70-80% are younger than 8 years of age at the time of clinical presentation. 3–5 A. References 1Blaney S, Kun LE, Hunter J, Rorke-Adams LB, Lau C, Strother D, Pollack IF. Tumors of the Central Nervous System. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology . Philadelphia: Lippincott Williams & Wilkins;2006:786–864 2Kutluk T, Yesilipek A, on behalf of Turkish Pediatric Oncology Group/Turkish Pediatric Hematology Association. Pediatric Cancer Registry. National Cancer Congress, 2007 3Goldwein JW, Leahy JM, Packer RJ, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys. 1990; 19:1497–1502. 4Gilles F, Sobel E, Tavaré C, et al. Age-related changes in diagnoses, histological features, and survival in children with brain tumors: 1930–1979. The Childhood Brain Tumor Consortium. Neurosurgery. 1995; 37:1056–1068. 5Polednak A, Flannery J. Brain, other central nervous system, and eye cancer. Cancer. 1995; 75:330–337. B. Clinical Signs and Symptoms Most children with ependymomas present with localized disease. The predominant location for this tumor is the posterior fossa; the main clinical signs and symptoms in young children with this tumor are irritability, lethargy, and gait disturbance.
    [Show full text]
  • Targeted Therapy with Sirolimus and Nivolumab in a Child with Refractory Multifocal Anaplastic Ependymoma
    Case Report Targeted Therapy with Sirolimus and Nivolumab in a Child with Refractory Multifocal Anaplastic Ependymoma Katia Perruccio 1,*, Angela Mastronuzzi 2 , Marco Lupattelli 3, Francesco Arcioni 1, Ilaria Capolsini 1, Carla Cerri 1, Grazia M. I. Gurdo 1, Maria Speranza Massei 1, Elena Mastrodicasa 1 and Maurizio Caniglia 1 1 Pediatric Oncology Hematology, Santa Maria della Misericordia Hospital, 06156 Perugia, Italy; [email protected] (F.A.); [email protected] (I.C.); [email protected] (C.C.); [email protected] (G.M.I.G.); [email protected] (M.S.M.); [email protected] (E.M.); [email protected] (M.C.) 2 Department of Hematology Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, 00165 Rome, Italy; [email protected] 3 Radiotherapy Department, Santa Maria della Misericordia Hospital, 06156 Perugia, Italy; [email protected] * Correspondence: [email protected] Abstract: Pediatric ependymoma (EPN) is the third most common central nervous system (CNS) tumor, with 90% arising intracranially. Management typically involves maximal surgical resection and radiotherapy, but patients’ outcome is poor. Moreover, there are only a few therapeutical options available for recurrent or refractory disease. In this report, we present the case of a 7-year-old girl with relapsed refractory multifocal grade III EPN who failed conventional treatments and experienced Citation: Perruccio, K.; Mastronuzzi, a stable and durable response to the immune checkpoint inhibitor (ICPI) nivolumab in association A.; Lupattelli, M.; Arcioni, F.; Capolsini, I.; Cerri, C.; Gurdo, G.M.I.; with the mammalian target of rapamycin (m-TOR) inhibitor sirolimus.
    [Show full text]
  • Assessment of Long Non-Coding RNA Expression Reveals Novel Mediators
    www.nature.com/scientificreports OPEN Assessment of long non‑coding RNA expression reveals novel mediators of the lung tumour immune response Adam P. Sage1,5, Kevin W. Ng1,5, Erin A. Marshall1*, Greg L. Stewart1, Brenda C. Minatel1, Katey S. S. Enfeld1, Spencer D. Martin1, Carolyn J. Brown2, Ninan Abraham3,4 & Wan L. Lam1 The tumour immune microenvironment is a crucial mediator of lung tumourigenesis, and characterizing the immune landscape of patient tumours may guide immunotherapy treatment regimens and uncover novel intervention points. We sought to identify the landscape of tumour‑ infltrating immune cells in the context of long non‑coding RNA (lncRNAs), known regulators of gene expression. We examined the lncRNA profles of lung adenocarcinoma (LUAD) tumours by interrogating RNA sequencing data from microdissected and non‑microdissected samples (BCCRC and TCGA). Subsequently, analysis of single‑cell RNA sequencing data from lung tumours and fow‑ sorted healthy peripheral blood mononuclear cells identifed lncRNAs in immune cells, highlighting their biological and prognostic relevance. We discovered lncRNA expression patterns indicative of regulatory relationships with immune‑related protein‑coding genes, including the relationship between AC008750.1 and NKG7 in NK cells. Activation of NK cells in vitro was sufcient to induce AC008750.1 expression. Finally, siRNA‑mediated knockdown of AC008750.1 signifcantly impaired both the expression of NKG7 and the anti‑tumour capacity of NK cells. We present an atlas of cancer‑ cell extrinsic immune cell‑expressed lncRNAs, in vitro evidence for a functional role of lncRNAs in anti‑ tumour immune activity, which upon further exploration may reveal novel clinical utility as markers of immune infltration.
    [Show full text]
  • Siglec10 As an Immunosuppressive and Tumorgenesis Signature for Prediction of Survival Prognosis in Gliomas
    Siglec10 as an Immunosuppressive and Tumorgenesis Signature for Prediction of Survival Prognosis in Gliomas Yanyan Feng Beijing University of Chinese Medicine Yuxiang Zhang Capital Medical University Sanbo Brain Hospital Ting Wang Beijing University of Chinese Medicine Yuyin Feng Beijing University of Chinese Medicine Hesong Wang Beijing University of Chinese Medicine Kai Yuan ( [email protected] ) Beijing University of Chinese Medicine https://orcid.org/0000-0001-7239-449X Primary research Keywords: Siglec10, prognosis, glioma, mechanism, biomarker Posted Date: July 14th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-40997/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/17 Abstract Background Glioma is a type of tumor occurring in central nervous system. Specic factors mutations and molecular abnormalities are used to conduct glioma classication and clinical decision in recent decade. Siglec10 is a member of sialic acid binding immunoglobulin superfamily. Methods We analyzed the siglec10 expression in glioma patients with immunohistochemical (IHC) staining method and evaluated the survival prognosis. Bioinformatic datasets including TCGA and CGGA were used to validate the IHC results. Functional enrichment analysis including GO, KEGG, and GSEA were conducted to study the related mechanism of siglec10, either. Results High siglec10 expression had shorter survival prognosis than low siglec10 expression in patients especially with malignant gliomas. Bioinformatic datasets including TCGA and CGGA validated the IHC results and discovered the expression of siglec10 was higher in malignant subtype than benign subtype of gliomas. So, siglec10 contributes to the poor prognosis of gliomas. Furthermore, the related mechanisms of siglec10 in gliomas were investigated by functional enrichment analysis including GSEA, GO, and KEGG analysis.
    [Show full text]
  • SIOP Ependymoma II Protocol V3.1 22 April 2020 Clean
    Ependymoma Program II FINAL Protocol Version 3. 1 April 22 th , 2020 An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma Final Version 3.1_ April 22 nd , 2020 Sponsor: Centre Léon Bérard Sponsor Protocol Number: ET-13-002 EudraCT Number: 2013-002766-39 VHP number: VHP358 (VHP201385) Page | 1 CONFIDENTIAL Ependymoma Program II FINAL Protocol Version 3. 1 April 22 th , 2020 SIGNATURE PAGE SIOP EPENDYMOMA II – An international Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma Protocol version 3.1 dated April 22 nd , 2020 This protocol has been approved by: Name: Dr David PEROL Trial Role: Medical and scientific coordinator Signature: _______________________________ Date: 22-Apr-2020 This protocol describes the SIOP Ependymoma Program II and provides information about procedures for patients taking part in this trial. The protocol should not be used as a guide for treatment of patients not taking part in the SIOP Ependymoma Program II. CONFIDENTIALITY NOTE: This trial protocol is the property of the authoring Coordinating Investigators and is protected by copyright. The content of the trial protocol and the case report forms is confidential and oral or written disclosure to any uninvolved / third parties (without previous written agreement by one of the international or national coordinating investigators) is prohibited. Page | 2 CONFIDENTIAL Ependymoma Program II FINAL Protocol Version 3. 1 April 22 th , 2020 AMENDMENTS
    [Show full text]
  • The Role of Histone Modifying Enzyme SUV420H2 in Pediatric Ependymoma
    W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 5-2015 The Role of Histone Modifying Enzyme SUV420H2 in Pediatric Ependymoma. Sarah Goggin College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Cancer Biology Commons, Genomics Commons, and the Molecular and Cellular Neuroscience Commons Recommended Citation Goggin, Sarah, "The Role of Histone Modifying Enzyme SUV420H2 in Pediatric Ependymoma." (2015). Undergraduate Honors Theses. Paper 215. https://scholarworks.wm.edu/honorstheses/215 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Table of Contents ABSTRACT:…………………………………………………………………………………………………………………….3 INTRODUCTION:…………………………………………………………………………………………………………..4 EPIGENETICS IN CANCER………………………………………………………………………………..……….5 GENE EXPRESSION PROFILING IN CANCER…………………………………………………….…………7 GENE EXPRESSION PROFILING IN PEDIATRIC EPENDYMOMA………………………………..…8 WHAT IS PEDIATRIC EPENDYMOMA?……………………………………………………………………………..9 ALTERED CHROMATIN STATES IN CANCER……………………………………………………………..12 ALTERED CHROMATIN STATES IN PEDIATRIC EPENDYMOMA…………………………………13 HISTONE MODIFYING ENZYME SUV4-20H2 EFFECT ON CHROMATIN STATE……………….13 METHODS:……………………………………………………………………………………………………………………16 ANALYSIS OF MICROARRAY DATA…………………………………………………………………………..16
    [Show full text]